The Role of Iron Imaging in Huntington's Disease

International Review of Neurobiology

Volumn 110, Issue , 2013, Pages 241-250

  Van den Bogaard, Simon J A ^a   Dumas, Eve M ^a   Roos, Raymund A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CAG; Huntingtin; Huntington's disease; Iron; MRI

Indexed keywords

IRON; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ARTICLE; BRAIN REGION; CAG REPEAT; EX VIVO STUDY; EXCITOTOXICITY; GENE; HTT GENE; HUMAN; HUNTINGTON CHOREA; IMAGE ANALYSIS; IN VIVO STUDY; IRON METABOLISM; NERVE CELL NECROSIS; NERVE FIBER TRANSPORT; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UNIFIED HUNTINGTON DISEASE RATING SCALE;

CAG; HUNTINGTIN; HUNTINGTON'S DISEASE; IRON; MRI;

ANIMALS; BRAIN; HUMANS; HUNTINGTON DISEASE; IRON; MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS;

EID: 84887224661     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-410502-7.00011-9     Document Type: Chapter

References (25)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes The Huntington's Disease Collaborative Research Group. Cell 1993, 72(6):971-983.
2. Aziz N.A., Anguelova G.V., Marinus J., van Dijk J.G., Roos R.A. Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease. European Journal of Neurology 2010, 17(8):1068-1074.
3. Aziz N.A., Pijl H., Frolich M., van der Graaf A.W., Roelfsema F., Roos R.A. Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. Journal of Clinical Endocrinology and Metabolism 2009, 94:1223-1228.
4. Bartzokis G., Cummings J., Perlman S., Hance D.B., Mintz J. Increased basal ganglia iron levels in Huntington disease. Archives of Neurology 1999, 56(5):569-574.
5. Bartzokis G., Lu P.H., Tishler T.A., Fong S.M., Oluwadara B., Finn J.P., et al. Myelin breakdown and iron changes in Huntington's disease: Pathogenesis and treatment implications. Neurochemical Research 2007, 32:1655-1664.
6. Browne S.E., Beal M.F. Oxidative damage in Huntington's disease pathogenesis. Antioxidants & Redox Signaling 2006, 8:2061-2073.
7. Chen J.C., Hardy P.A., Kucharczyk W., Clauberg M., Joshi J.G., Vourlas A., et al. MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR. American Journal of Neuroradiology 1993, 14:275-281.
8. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114(Pt 4):1953-1975.
9. Dumas E.M., Versluis M.J., van den Bogaard S.J., van Osch M.J., Hart E.P., van Roon-Mom W.M., et al. Elevated brain iron is independent from atrophy in Huntington's disease. NeuroImage 2012, 61:558-564.
10. Estrada Sanchez A.M., Mejia-Toiber J., Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Archives of Medical Research 2008, 39:265-276.
11. Firdaus W.J., Wyttenbach A., Giuliano P., Kretz-Remy C., Currie R.W., Arrigo A.P. Huntingtin inclusion bodies are iron-dependent centers of oxidative events. FEBS Journal 2006, 273:5428-5441.
12. Hilditch-Maguire P., Trettel F., Passani L.A., Auerbach A., Persichetti F., MacDonald M.E. Huntingtin: An iron-regulated protein essential for normal nuclear and perinuclear organelles. Human Molecular Genetics 2000, 9:2789-2797.
13. Jurgens C.K., Jasinschi R., Ekin A., Witjes-Ane M.N., Middelkoop H., van der Grond J., et al. MRI T2 hypointensities in basal ganglia of premanifest Huntington's disease. PLoS Currents 2010, 2.
14. Lumsden A.L., Henshall T.L., Dayan S., Lardelli M.T., Richards R.I. Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Human Molecular Genetics 2007, 16(16):1905-1920.
15. Morrison P.J., Nevin N.C. Serum iron, total iron binding capacity and ferritin in early Huntington disease patients. Irish Journal of Medical Science 1994, 163:236-237.
16. Novak M.J., Tabrizi S.J. Huntington's disease. BMJ 2010, 340:c3109.
17. Paulsen J.S., Nopoulos P.C., Aylward E., Ross C.A., Johnson H., Magnotta V.A., et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Research Bulletin 2010, 82:201-207.
18. Ross C.A., Tabrizi S.J. Huntington's disease: From molecular pathogenesis to clinical treatment. Lancet Neurology 2011, 10:83-98.
19. Roze E., Saudou F., Caboche J. Pathophysiology of Huntington's disease: From huntingtin functions to potential treatments. Current Opinion in Neurology 2008, 21:497-503.
20. Simmons D.A., Casale M., Alcon B., Pham N., Narayan N., Lynch G. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 2007, 55:1074-1084.
21. Sturrock A., Leavitt B.R. The clinical and genetic features of Huntington disease. Journal of Geriatric Psychiatry and Neurology 2010, 23:243-259.
22. Tabrizi S.J., Langbehn D.R., Leavitt B.R., Roos R.A., Durr A., Craufurd D., et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurology 2009, 8:791-801.
23. Vonsattel J.P., Keller C., Cortes Ramirez E.P. Huntington's disease-Neuropathology. Handbook of Clinical Neurology 2011, 100:83-100.
24. Vymazal J., Klempir J., Jech R., Zidovska J., Syka M., Ruzicka E., et al. MR relaxometry in Huntington's disease: Correlation between imaging, genetic and clinical parameters. Journal of Neurological Sciences 2007, 263:20-25.
25. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nature Review Neuroscience 2004, 5:863-873.